Clinical trial readout dates for Spyre Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2027.
| Phase 2 SPY001 Ulcerative Colitis; Inflammatory Bowel Diseases · NCT07012395 | June 2027 Recruiting |
| Phase 2 SPY072 Hidradenitis Suppurativa (HS) · NCT07766005 | October 2027 Recruiting |
| Phase 2 SPY001 Ulcerative Colitis; Inflammatory Bowel Diseases · NCT07652294 | March 2029 Enrolling |
Spyre Therapeutics Inc. reported $1.10B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $96M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |